UA102370C2 - Пептид, фармацевтическая композиция и лекарственное средство, которое его содержит, способ лечения и/или предупреждения диабета и сопутствующих ожирению заболеваний, способ снижения аппетита, снижение поглощения пищи и снижение массы тела - Google Patents
Пептид, фармацевтическая композиция и лекарственное средство, которое его содержит, способ лечения и/или предупреждения диабета и сопутствующих ожирению заболеваний, способ снижения аппетита, снижение поглощения пищи и снижение массы телаInfo
- Publication number
- UA102370C2 UA102370C2 UAA200907137A UAA200907137A UA102370C2 UA 102370 C2 UA102370 C2 UA 102370C2 UA A200907137 A UAA200907137 A UA A200907137A UA A200907137 A UAA200907137 A UA A200907137A UA 102370 C2 UA102370 C2 UA 102370C2
- Authority
- UA
- Ukraine
- Prior art keywords
- glu15
- tyr21 phe22
- lys20 tyr21
- val19 lys20
- glu24
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Изобретение относится к пептиду, который включает нижеследующую последовательность аминокислот Xaa1 Xaa2 Xaa3 Gly4 Thr5 Phe6 Thr7 Ser8 Asp9 Tyr10 Ser11 Lys12 Tyr13 Leu14 Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Trp25 Leu26 Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 Lys33 Asn34 Asn35 Ile36 Ala37; где: Xaa1 представляет собой D-His1 или His1, Xaa2 представляет собой Ala2 или Ser2, Xaa3 представляет собой Gln3 или Asp3, Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 представляет собой: Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24, Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Glu16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Gln24, Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Glu16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24, Glu15 Gln16 Glu17 Leu18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Glu24, Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Leu23 Gln24 или Glu15 Gln16 Glu17 Ile18 Val19 Lys20 Tyr21 Phe22 Ile23 Glu24; Xaa27 Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 представляет собой: Lys27 Asn28 Ala29 Gly30 Pro31 Ser32, или Lys27 Asn28 Gly29 Gly30 Pro31 Ser32 или пептид, как приведено выше, в котором остаток Asn34 заменен Asp34, или пептид, как приведено выше, в котором Xaa3 представляет собой Glu33, к применению пептида как супрессора аппетита, а также при лечении/предупреждении ожирения, диабета и/или заболеваний, сопутствующих ожирению.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0624868.6A GB0624868D0 (en) | 2006-12-13 | 2006-12-13 | Novel compounds and their effects on feeding behaviour |
| PCT/GB2007/004779 WO2008071972A1 (en) | 2006-12-13 | 2007-12-13 | Novel compounds and their effects on feeding behaviour |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA102370C2 true UA102370C2 (ru) | 2013-07-10 |
Family
ID=37712059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200907137A UA102370C2 (ru) | 2006-12-13 | 2007-12-13 | Пептид, фармацевтическая композиция и лекарственное средство, которое его содержит, способ лечения и/или предупреждения диабета и сопутствующих ожирению заболеваний, способ снижения аппетита, снижение поглощения пищи и снижение массы тела |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN101578107B (ru) |
| GB (1) | GB0624868D0 (ru) |
| UA (1) | UA102370C2 (ru) |
| ZA (1) | ZA200903770B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3878859T3 (da) | 2011-06-10 | 2024-01-02 | Hanmi Science Co Ltd | Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse |
| HUE042585T2 (hu) | 2011-06-17 | 2019-07-29 | Hanmi Science Co Ltd | Oxintomodulint és immunglobulin-fragmentumot tartalmazó konjugátum és alkalmazása |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| EP2916819B1 (en) | 2012-11-06 | 2019-07-10 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| CN1189480C (zh) * | 2002-03-25 | 2005-02-16 | 中国科学院昆明动物研究所 | 饱食因子及其制备方法 |
| WO2005035761A1 (en) * | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
-
2006
- 2006-12-13 GB GBGB0624868.6A patent/GB0624868D0/en not_active Ceased
-
2007
- 2007-12-13 CN CN200780044820.9A patent/CN101578107B/zh not_active Expired - Fee Related
- 2007-12-13 UA UAA200907137A patent/UA102370C2/ru unknown
-
2009
- 2009-05-29 ZA ZA200903770A patent/ZA200903770B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101578107B (zh) | 2014-03-19 |
| GB0624868D0 (en) | 2007-01-24 |
| ZA200903770B (en) | 2010-05-26 |
| CN101578107A (zh) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006348A (es) | Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion. | |
| UA102370C2 (ru) | Пептид, фармацевтическая композиция и лекарственное средство, которое его содержит, способ лечения и/или предупреждения диабета и сопутствующих ожирению заболеваний, способ снижения аппетита, снижение поглощения пищи и снижение массы тела | |
| JP2009529553A5 (ru) | ||
| JP2005534647A5 (ru) | ||
| CA2309356A1 (en) | Novel exendin agonist compounds | |
| JP2008514624A5 (ru) | ||
| de Rougemont et al. | Preconditioning, organ preservation, and postconditioning to prevent ischemia‐reperfusion injury to the liver | |
| de Rougemont et al. | Biological modulation of liver ischemia–reperfusion injury | |
| W. POTTS et al. | The effects of hypophysectomy and bovine prolactin on salt fluxes in fresh-water-adapted Fundulus heteroclitus | |
| Huijink et al. | Metformin preconditioning and postconditioning to reduce ischemia reperfusion injury in an isolated ex vivo rat and porcine kidney normothermic machine perfusion model | |
| Fröhlich et al. | Induced hypothermia reduces the hepatic inflammatory response in a swine multiple trauma model | |
| FR2839722A1 (fr) | Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c | |
| Cisco | ||
| Cisco | ||
| Cisco | ||
| Cisco | ||
| Miller | Overview of the efficacy and safety of SGLT-2 inhibitors in type 2 diabetes mellitus | |
| Egers et al. | Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit | |
| Meng et al. | Auxiliary Therapeutic Effects of Emodin on Diabetic Nephropathy | |
| Bezeljak et al. | Pathophysiological changes and systemic inflammation in brain dead organ donors: effect on graft quality | |
| Daniels | Andrew Luck Announces His Retirement Two Weeks Before the Start of the 2019 Season | |
| Saini | Periodontitis: A risk factor for pre-eclampsia | |
| Alsabbagh | Peginterferon-α-2a/ribavirin | |
| Chan et al. | Weight loss in the renal transplant candidate: A clinical review of the efficacy of conservative and surgical treatments.: Abstract# B911 | |
| Pechman | Metoprolol overdose |